Mateon Therapeutics (MATN) is Resumed by Rodman & Renshaw to Buy, Price Target at $2

Mateon Therapeutics (MATN) was Resumed by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $2. Rodman & Renshaw advised their investors in a research report released on Aug 22, 2016.

Mateon Therapeutics

Leave a Reply

Mateon Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Mateon Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.